NORDIC BIOTECH ADVISORS ApS: Financial statements 2023
CVR: 26123925
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
NORDIC BIOTECH ADVISORS ApS (CVR 26123925) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK 4,495,918 and a net result of DKK 1,432,611 compared with DKK 942,698 the year before. That is an increase of 17.9% compared with the year before. Equity in the 2023 report amounted to DKK 4,834,429. The solvency ratio was 92%. The company had 2 employees in the financial year.
- Gross Profit
- DKK 4,495,918
- Profit/Loss
- DKK 1,432,611
- Equity
- DKK 4,834,429
- Total Assets
- DKK 5,254,668
- Employees
- 2
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | 4.5M | 1.4M | 4.8M | 2 |
| 2022 | - | 3.8M | 943K | 3.4M | 2 |
| 2021 | - | 3.7M | 657K | 2.5M | 2 |
| 2020 | - | 2.7M | -301K | 1.8M | 2 |
| 2019 | - | 3.3M | 81K | 2.1M | 2 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record, straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
NORDIC BIOTECH ADVISORS ApS has published its annual report for 2022. Gross profit came to DKK 3,812,316, and the net result was DKK 942,698.
About NORDIC BIOTECH ADVISORS ApS
NORDIC BIOTECH ADVISORS ApS is a Danish company of the type Anpartsselskab based in Hellerup, founded in 2001. The company is registered under the industry Andre aktiviteter i forbindelse med finansielle tjenesteydelser, undtagen forsikring og pensionsforsikring. The company was previously named NEXGEN BIOTECH ApS and NORDIC BIOTECH ApS. The management consists of Florian Schønharting. The board consists of Florian Schønharting and Jakob Mosegaard Larsen. The company is owned by TECH GROWTH INVEST ApS, C. HANSEN INVEST ApS and BVF/Nexgen Biotech, LP. The company has 2 employees (2026). In 2025, the company reported a gross profit of DKK 3,273,154 and a net result of DKK 360,368 compared with DKK -572,578 the year before. Equity in the 2025 report amounted to DKK 4,622,219.
